Antimicrobial sensitisers: Gatekeepers to avoid the development of multi-drug-resistant bacteria.
Antibiotic adjuvant
Antimicrobial sensitizer
Indirect antibacterial
Multidrug-resistant bacteria
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
18 Mar 2024
18 Mar 2024
Historique:
received:
24
10
2023
revised:
23
02
2024
accepted:
16
03
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
20
3
2024
Statut:
aheadofprint
Résumé
The resistance of multidrug-resistant bacteria to existing antibiotics forces the continued development of new antibiotics and antibacterial agents, but the high costs and long timeframe involved in the development of new agents renders the hope that existing antibiotics may again play a part. The "antibiotic adjuvant" is an indirect antibacterial strategy, but its vague concept has, in the past, limited the development speed of related drugs. In this review article, we put forward an accurate concept of a "non-self-antimicrobial sensitisers (NSAS)", to distinguish it from an "antibiotic adjuvant", and then discuss several scientific methods to restore bacterial sensitivity to antibiotics, and the sources and action mechanism of existing NSAS, in order to guide the development and further research of NSAS.
Identifiants
pubmed: 38508527
pii: S0168-3659(24)00184-6
doi: 10.1016/j.jconrel.2024.03.031
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors have none conflicts to declare.